References
- Davies BI, Maesen FP. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J Antimicrob Chemother 1999; 43 Suppl C:83–90.
- De Abate CA, Russel M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis. Respir Care 1997; 42: 206–13.
- Habib MP, Russell M, De Abate CA, et al. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in the treatment of acute exacerbations of chronic bronchitis. Infect Dis Clin Practice 1998; 7: 1–9.
- Shah PM, Maesen FP, Dolmann A, et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother 1999; 43: 529–39.
- Weiss LR. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin Ther 2002; 24: 1414–25.
- Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbations of chronic bronchitis. Int J Antimicrob Agents 2001; 18: 503–12.
- File TM, Segreti J, Dubar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965–72.
- Geddes AM, Thaler M, Schonwald S, et al. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/ cilastatin in an open, randomised trial. J Antimicrob Chemother 1999; 44: 799–810.
- Sullivan J, McElroy AD, Honsinger RW, et al. Treating community-acquired pneumonia with once daily gatifloxacin vs. once daily levofloxacin. J Respir Dis 1999; 20 (S11): 49s-59s.
- Ball P, Fernald A, Tillotson G. Therapeutical advances of new fluoroquinolones. Expert Opin Invest Drugs 1998; 7: 761–83.
- Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug- Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399–408.